Search Results - "Buus, R"

OX40 and 4-1BB delineate distinct immune profiles in sarcoma by Melake, MJ, Smith, HG, Mansfield, D, Davies, E, Dillon, MT, Wilkins, AC, Patin, EC, Pedersen, M, Buus, R, Melcher, AA, Thway, K, Miah, AB, Zaidi, SH, Hayes, AJ, Fenton, TR, Harrington, KJ, McLaughlin, M

“…Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy…”
Get full text

Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials by Sestak, I., Filipits, M., Buus, R., Rudas, M., Knauer, M., Kronenwett, R., Cuzick, J., Gnant, M.I., Dowsett, M., Dubsky, P.

Get full text

Effects of a Monoclonal Antibody Raised Against Nerve Growth Factor on Skeletal Pain and Bone Healing After Fracture of the C57BL/6J Mouse Femur by Koewler, Nathan J, Freeman, Katie T, Buus, Ryan J, Herrera, Monica B, Jimenez‐Andrade, Juan M, Ghilardi, Joseph R, Peters, Christopher M, Sullivan, Lucy J, Kuskowski, Michael A, Lewis, Jack L, Mantyh, Patrick W

“…A closed femur fracture pain model was developed in the C57BL/6J mouse. One day after fracture, a monoclonal antibody raised against nerve growth factor…”
Get full text

Transferrin Expression by Placental Trophoblastic Cells by MorrisBuus, R., Boockfor, F.R.

“…Transferrin (TF), a 76–80 kDa glycoprotein, is responsible for the transport of iron to cells within both the fetal and maternal systems, but it does not cross…”
Get full text

PIH46 - Changes in Fda Post-Marketing Commitments to Support The Pregnancy and Lactation Labeling Rule by Covington, D, Buus, R, Mabe, B

Get full text

Changes in Fda Post-Marketing Commitments to Support The Pregnancy and Lactation Labeling Rule by Covington, D, Buus, R, Mabe, B

Get full text

REFERENCE GROUPS USED IN PREGNANCY EXPOSURE REGISTRIES: CHALLENGES AND OPPORTUNITIES by Covington, D, Buus, R, Blum, C

“…OBJECTIVES: Pregnancy registries monitor pregnancies exposed to specific drugs to determine risk of major birth defects. Ideally, registries should be designed…”
Get full text

Abstract P2-04-07: Immune profiling of post neoadjuvant high metastatic risk (RCB-II/III) residual disease in patients with early triple negative breast cancers by Irshad, S, Cheang, M, Gazinka, P, Naidoo, K, Buus, R, Pinder, S, Dowsett, M, Tutt, A

“…Abstract Background: Poor prognosis in TNBC can be predicted in the significant fraction of patients with large volume residual cancer burden (RCB-II/III)…”
Get full text

PMS76 - HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH REFRACTORY MYASTHENIA GRAVIS (MG), IN COMPARISON TO NON-REFRACTORY MG PATIENTS IN ENGLAND: A RETROSPECTIVE COHORT STUDY by Graham, S., MacLachlan, S., Exuzides, A., Buus, R., Harris, L., Jacob, S.

Get full text

2OPrognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials by Sestak, I, Filipits, M, Buus, R, Rudas, M, Knauer, M, Kronenwett, R, Cuzick, J, Gnant, M I, Dowsett, M, Dubsky, P

Get full text

Abstract P2-08-04: Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET+C) or endocrine therapy alone (ET) by Sestak, I, Martin, M, Dubsky, P, Rojo, F, Cuzick, J, Filipits, M, Ruiz, A, Buus, R, Hlauschek, D, Rodriguez-Lescure, A, Dowsett, M, Gnant, M

“…Abstract Background: EndoPredict (EPclin) is a validated prognostic test combining expression of 12 cancer-related genes for breast cancer patients with…”
Get full text

Abstract P4-15-01: Acquired ESR1 mutation and persistent expression of estrogen regulated genes in ER+ breast cancers on long-term neoadjuvant treatment with aromatase inhibitors by Leal, MF, Haynes, BP, Schuster, E, Yeo, B, Afentakis, M, Dodson, A, Buus, R, Cheang, MC, Martin, L-A, Dowsett, M

“…Abstract Background: Aromatase inhibitors (AI), which block the conversion of androgen to estrogen, are the mainstay therapy for estrogen receptor–positive…”
Get full text

Abstract PD5-05: Genomic instability and poor antiproliferative response to aromatase inhibitor treatment: A POETIC study by Schuster, EF, Gellert, P, Segal, CV, López-Knowles, E, Buus, R, Morden, J, Robertson, J, Bliss, J, Smith, I, Dowsett, M

“…Abstract Background: More than 20% of early-stage patients with estrogen positive (ER+) disease relapse. Higher levels of the proliferation marker Ki67, and…”
Get full text

Peripapillary crescents and halos in normal-tension glaucoma and ocular hypertension by Buus, D R, Anderson, D R

“…In normal-tension glaucoma ("low-tension" glaucoma), 21 of 33 eyes (64%) had a peripapillary chorioscleral crescent or halo, compared with 13 of 38 eyes (34%)…”
Get more information

A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma by Huang, P., Lee, A., McCarthy, F., Thway, K., Morden, J., Messiou, C., Daley, F., Buus, R., Fisher, C., Cheang, M., Judson, I., Jones, R.

Get full text

Abstract S3-01: EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS) by Dowsett, M, Sestak, I, Buus, R, Kronenwett, R, Denkert, C, Krappmann, K, Scheer, M, Petry, C, Dubsky, P, Cuzick, J

“…Abstract Background: RS is widely used for estimating 10-yr risk of DR for br ca patients receiving 5yrs adjuvant endocrine treatment alone. EndoPredict is a…”
Get full text

Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC by Sestak, I, Buus, R, Cuzick, J, Dubsky, P, Kronenwett, R, Ferree, S, Sgroi, D, Schnabel, C, Baehner, R, Mallon, E, Dowsett, M

“…Abstract Background: A number of prognostic signatures have been developed for the prediction of breast cancer recurrence in the past decade. We have developed…”
Get full text

Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2- breast cancer by Dowsett, M, Sestak, I, Buus, R, Lopez-Knowles, E, Cuzick, J

“…The Oncotype Dx(R) 21-gene Recurrence Score (RS) measures risk of distant recurrence (REC) in patients with ER[sup +] primary breast cancer receiving endocrine…”
Get full text

Ophthalmic complications of sinus surgery by Buus, D R, Tse, D T, Farris, B K

“…Seven patients with orbital complications of sinus surgery seen over a 10-year period are reported. Severe intraoperative orbital hemorrhage occurred in three…”
Get more information

Genetic epidemiologic studies of preterm birth: guidelines for research by Pennell, Craig E., MD, PhD, Jacobsson, Bo, MD, PhD, Williams, Scott M., PhD, Buus, Rebecca M., PhD, Muglia, Louis J., MD, PhD, Dolan, Siobhan M., MD, MPH, Morken, Nils-Halvdan, MD, Ozcelik, Hilmi, PhD, Lye, Stephen J., PhD, Relton, Caroline, PhD

“…Over the last decade, it has become increasingly apparent that the cause of preterm birth is multifactorial, involving both genetic and environmental factors…”
Get full text